Leerink Partners Maintains Outperform on AnaptysBio, Raises Price Target to $85
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $66 to $85.
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $66 to $85.